By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > SGLT2 inhibitor > Empagliflozin

Empagliflozin

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|656 words

Empagliflozin Drug Profile

What is Empagliflozin?

Empagliflozin is a prescription medication belonging to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. It is primarily used to treat type 2 diabetes mellitus and has additional cardiovascular benefits. This oral medication works by preventing the kidneys from reabsorbing glucose back into the bloodstream, allowing excess sugar to be eliminated through urine.

Uses

Empagliflozin has several approved therapeutic uses:

  • Type 2 diabetes management: Used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
  • Cardiovascular risk reduction: Reduces the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
  • Heart failure treatment: Reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure
  • Chronic kidney disease: Slows the progression of kidney disease in adults with chronic kidney disease at risk of progression
  • Combination therapy: Often used alongside other diabetes medications like metformin when single-drug therapy is insufficient

How it works

Empagliflozin blocks SGLT2 receptors in the kidneys, which are responsible for reabsorbing about 90% of filtered glucose back into the bloodstream. By inhibiting these receptors, the medication causes excess glucose to be eliminated through urine, effectively lowering blood sugar levels. This mechanism also leads to modest weight loss and blood pressure reduction due to the loss of calories and fluid through increased urination.

Side effects

Common side effects:

Submit Your Paper
GMJ_Submit_Banner
  • Urinary tract infections
  • Increased urination
  • Thirst
  • Genital yeast infections
  • Nausea
  • Upper respiratory tract infections
  • Low blood pressure
  • Dehydration

Serious side effects requiring immediate medical attention:

  • Diabetic ketoacidosis (even with normal blood sugar levels)
  • Serious urinary tract infections that may spread to kidneys
  • Necrotizing fasciitis of the perineum (Fournier’s gangrene)
  • Severe dehydration leading to kidney injury
  • Bone fractures

Warnings and precautions

  • Kidney function monitoring: Should be used cautiously in patients with reduced kidney function, and kidney function should be monitored regularly during treatment
  • Pregnancy and breastfeeding: Not recommended during pregnancy, especially in the second and third trimesters, as it may harm the developing kidneys; breastfeeding is not recommended while taking this medication
  • Diabetic ketoacidosis risk: Patients should be educated about signs and symptoms of ketoacidosis, which can occur even when blood glucose levels are not severely elevated
  • Surgery and illness: May need to be temporarily discontinued during periods of illness, surgery, or other stress that could lead to dehydration
  • Elderly patients: Increased risk of dehydration and low blood pressure in patients over 65 years of age

Interactions

  • Insulin and insulin secretagogues: Increased risk of hypoglycemia when combined with sulfonylureas or insulin; dosage adjustments may be necessary
  • Diuretics: Enhanced diuretic effect may lead to dehydration and low blood pressure when combined with thiazide or loop diuretics
  • ACE inhibitors and ARBs: Combination may increase risk of kidney problems and low blood pressure
  • Lithium: May increase lithium levels in the blood, requiring closer monitoring
  • Digoxin: Potential for increased digoxin levels due to kidney function changes
  • NSAIDs: May increase risk of kidney injury when used together
  • Alcohol: May increase risk of dehydration and low blood sugar
  • Herbal supplements: St. John’s wort may affect blood sugar control

Check interactions with the GMJ Interaction Checker

Dosage

For adults with type 2 diabetes, the typical starting dose is 10 mg once daily, taken in the morning with or without food. The dose may be increased to 25 mg once daily if additional glycemic control is needed and the medication is well tolerated. For heart failure or chronic kidney disease, the recommended dose is 10 mg once daily. Dosage adjustments are necessary for patients with moderate to severe kidney impairment. The medication should be discontinued if kidney function falls below certain thresholds. All dosing decisions should be individualized and determined by a healthcare provider based on the patient’s specific condition, kidney function, and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Empagliflozin." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/empagliflozin/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Rare Earth Mining Creates Hidden Public Health Crisis in Myanmar

Rare earth mining operations in Myanmar are creating an unmonitored environmental health…

Language Barriers in Healthcare: How Communication Gaps Affect Patient Safety and Quality of Care

Language barriers in healthcare contribute to 25% of medical errors in multicultural…

New Clinical Guidelines Address Heart-Brain Multimorbidity Management

New clinical practice guidelines published in CMAJ provide evidence-based recommendations for managing…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Dapagliflozin

By
Prof. Giorgi Pkhakadze
02/06/2026

Canagliflozin

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up